Evidence map›Paper›PMID 32873215›Full record

ArticleEmerging microbes & infections2020

Interferon-gamma-activated macrophages infected with Burkholderia cenocepacia process and present bacterial antigens to T-cells by class I and II major histocompatibility complex molecules.

Roberto Rosales-Reyes, Paola Garza-Villafuerte, Daniela Vences-Vences, Daniel F Aubert, Rubi Aca-Teutle, Vianney F Ortiz-Navarrete, Laura C Bonifaz, Julio Cesar Carrero-Sánchez, Alfonso Olivos-García, Miguel A Valvano and 1 more

Open access · goldAbstract read
In one paragraph

Article in Emerging microbes & infections, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Frontiers in immunology · 2026
    Article
  3. Article
  4. Bacterial Subversion of Autophagy in Cystic Fibrosis.Frontiers in cellular and infection microbiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 5 countries.

Roberto Rosales-ReyesFacultad de Medicina, Unidad de Investigación en Medicina Experimental, Universidad Nacional Autónoma de México, Mexico City, México.ORCID https://orcid.org/0000-0001-9519-8766
Paola Garza-VillafuerteFacultad de Medicina, Unidad de Investigación en Medicina Experimental, Universidad Nacional Autónoma de México, Mexico City, México.ORCID https://orcid.org/0000-0001-9102-2448
Daniela Vences-VencesFacultad de Medicina, Unidad de Investigación en Medicina Experimental, Universidad Nacional Autónoma de México, Mexico City, México.ORCID https://orcid.org/0000-0003-1409-8646
Daniel F AubertDepartment of Microbiology and Immunology, The University of Western Ontario, London, Canada.ORCID https://orcid.org/0000-0003-2409-3654
Rubi Aca-TeutleFacultad de Medicina, Unidad de Investigación en Medicina Experimental, Universidad Nacional Autónoma de México, Mexico City, México.ORCID https://orcid.org/0000-0001-7833-4973
Vianney F Ortiz-NavarreteDepartamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del IPN, Mexico City, México.ORCID https://orcid.org/0000-0001-6546-9713
Laura C BonifazUnidad de Investigación Médica en Inmunoquímica Hospital de Especialidades Centro Médico Nacional Siglo XXI, IMSS, Mexico City, Mexico.ORCID https://orcid.org/0000-0001-8482-5648
Julio Cesar Carrero-SánchezInstituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID https://orcid.org/0000-0003-1055-5774
Alfonso Olivos-GarcíaFacultad de Medicina, Unidad de Investigación en Medicina Experimental, Universidad Nacional Autónoma de México, Mexico City, México.ORCID https://orcid.org/0000-0001-9864-2818
Miguel A ValvanoDepartment of Microbiology and Immunology, The University of Western Ontario, London, Canada.ORCID https://orcid.org/0000-0001-8229-3641
José Ignacio Santos-PreciadoFacultad de Medicina, Unidad de Investigación en Medicina Experimental, Universidad Nacional Autónoma de México, Mexico City, México.ORCID https://orcid.org/0000-0001-9298-2926
National Autonomous University of Nicaragua · NIWestern University · CACentro Medico Nacional Siglo XXI · MXInstituto de Estudios Avanzados · VEUniversidad Nacional Autónoma de México · MX

Funding

Medical Research Council MR/P022480/1
6 · The paper itself

Abstract

Burkholderia cenocepacia is an emerging opportunistic pathogen for people with cystic fibrosis and chronic granulomatous disease. Intracellular survival in macrophages within a membrane-bound vacuole (BcCV) that delays acidification and maturation into lysosomes is a hallmark of B. cenocepacia infection. Intracellular B. cenocepacia induce an inflammatory response leading to macrophage cell death by pyroptosis through the secretion of a bacterial deamidase that results in the activation of the pyrin inflammasome. However, how or whether infected macrophages can process and present B. cenocepacia antigens to activate T-cells has not been explored. Engulfed bacterial protein antigens are cleaved into small peptides in the late endosomal major histocompatibility class II complex (MHC) compartment (MIIC). Here, we demonstrate that BcCVs and MIICs have overlapping features and that interferon-gamma-activated macrophages infected with B. cenocepacia can process bacterial antigens for presentation by class II MHC molecules to CD4

Indexed as

AnimalsAntigen PresentationAntigens, BacterialBurkholderia cenocepaciaBurkholderia InfectionsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Culture TechniquesCells, CulturedHistocompatibility Antigens Class IHistocompatibility Antigens Class IIInterferon-gammaMacrophagesMiceAntigens, BacterialHistocompatibility Antigens Class IHistocompatibility Antigens Class IIInterferon-gammaantigen presentationantigen processingBurkholderia cepacia complexMIICRab7T-cell activationType 6 secretion

Identifiers

PMID32873215
PMCPMC7534305
OpenAlexW3082242204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.